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In the accompanying Comment1, Suzuki et al. confirmed our previous 
findings2 that the ketamine metabolite (2R,6R)-hydroxynorketamine 
(HNK) does not functionally inhibit the NMDAR at concentrations 
relevant to its antidepressant actions recently reported in mice (that 
is, approximately 10 μM). We reported that 10 μM (2R,6R)-HNK, 
which equates to the maximum concentration of brain exposure 
(10.69 μM (ref. 2)) after intraperitoneal administration of a 10 mg kg−1 
anti depressant dose of (2R,6R)-HNK in mice, robustly potentiated 
excitatory postsynaptic potentials in hippocampal slices without func-
tionally inhibiting the NMDAR2, as Suzuki et al. now confirm. Unless 
NMDAR inhibition is observed at 10 μM (2R,6R)-HNK, it is probably 
not of major relevance to the antidepressant actions of (2R,6R)-HNK. 
Notably, (2R,6R)-HNK administration also resulted in significant anti-
depressant actions at the dose of 5 mg kg−1 in mice, which would 
produce even lower concentrations of the metabolite in the brain 
than 10 μM (ref. 2). Furthermore, our field-potential electrophysio-
logy experiments were conducted in the presence of the NMDAR 
antagonist AP5 (80 μM), demonstrating that the AMPAR-mediated 
synaptic potentiation we observed is indepen dent of any capacity of 
(2R,6R)-HNK to inhibit the NMDAR.
We agree with Suzuki et al. that assessing higher concentrations of 
(2R,6R)-HNK on NMDAR-mediated miniature excitatory postsyn-
aptic currents (NMDAR-mEPSCs) responses might be important in 
providing information for off-target effects of this metabolite, and their 
study indeed  provides evidence for a modest inhibition (~ 37%) at the 
concentration of 50 μ M. The absence of Mg2+ in the testing condi-
tions may influence the apparent discrepancy between 37% inhibition 
of NMDAR-mEPSCs at the 50 μ M concentration (for example, as is 
the case with  memantine, which only inhibits NMDAR-mEPSCs in 
the absence of Mg2+, and does not have antidepressant properties in 
humans3), and the previously reported lack of displacement of [3H] 
MK-801 binding at less than 100 μ M (ref. 4). It will be important to 
follow up on this finding with a full concentration response curve in 
order to determine the half maximal inhibi tory concentration (IC50) 
of (2R,6R)-HNK on NMDAR-mEPSC responses, and to compare to 
the IC50 of (R,S)-ketamine, under the same conditions using physiolo-
gical levels of Mg2+. Notably, we did not observe NMDAR-inhibition-
associated psychostimulant, self-administration, drug discrimination 
and pre-pulse inhibition side effects of (2R,6R)-HNK at any dose, 
including up to 375 mg kg−1 (ref. 2).
The authors also observed decreased phosphorylation of the eukar-
yotic elongation  factor 2 (eEF2) only at the concentration of 50 μ M. 
Although this is the same high concentration at which (2R,6R)-HNK 
induced an inhibition of the NMDAR responses, these data do not 
provide direct evidence of a functional link between the moderate 
inhibition of NMDARs and the decrease in eEF2 phosphorylation. 
Indeed there are multiple mechanisms other than NMDAR inhibi-
tion that could be responsible for the observed eEF2 dephosphoryl-
ation5–8. It is also important to note that although direct application 
of ketamine9 or the alternative NMDAR blocker MK-801 (ref. 10) 
to cultured neurons or hippocampal slices was previously reported 
to induce NMDAR-inhibition-dependent synaptic potentiation, 
MK-801 has repeatedly failed to induce  ketamine-like  sustained anti-
depressant effects in several animal tests2,9,11,12. It is  therefore probable  
that synaptic strengthening as a consequence of NMDAR inhibition 
(proposed by Suzuki et al.) is not solely  responsible for the antidepres-
sant actions of ketamine. Indeed, the results of clinical trials indicate 
that several other NMDAR antagonists lack the full antidepressant 
actions of ketamine in humans13.
Suzuki et al. also propose that NMDAR inhibition by (R,S)-
ketamine is responsible for the initiation of antidepressant responses 
(that is, the acute actions), and HNK metabolites mediate the long-
term antidepressant effects of ketamine through continued NMDAR 
inhibition. This hypothesis is not supported by our pharmacokinetic 
measurements of ketamine and its metabolites in the brain of mice 
following intraperitoneal administration of (R,S)-ketamine, which 
show that both ketamine and its metabolites peak at similar early time 
points, have a similar short half-life, and are below detectable levels by 
four hours after treatment2. 
In conclusion, the data presented by Suzuki et al. further support 
an NMDAR-inhibition-independent mechanism of antidepressant 
action of the ketamine metabolite (2R,6R)-HNK at physiologically 
relevant concentrations. Although development of (2R,6R)-HNK as 
an anti depressant drug, which does not induce NMDAR-mediated 
side effects, can proceed independently of target identification, it 
remains important to identify its primary pharmacological target at 
anti depressant-relevant concentrations (~ 10 μ M).
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